Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Inc. (NASDAQ:GILD) in its Q1 2025 investor letter: "Health care stocks populated our top performers for the quarter. Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ:GILD) announced strong ...

Shares of Gilead Sciences Inc. GILD shed 2.21% to $103.19 Tuesday ... at record speed and with unparalleled accuracy. Back To Top ...

Efforts to build a cancer franchise have been mixed; notable acquisitions include Kite Pharma, Forty Seven Inc., and Immunomedics, with varying degrees of success ... The top two have netted ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research ... Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV). The company’s broad portfolio includes drugs for liver ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.